Rachna Begh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachna Begh has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Paul Aveyard
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
14 shared publications - Nicola Lindson
Nuffield Department of Primary Care Health Sciences University of Oxford Oxford UK
6 shared publications - Aziz Sheikh
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
4 shared publications - Amanda Amos
Usher Institute, University of Edinburgh, Edinburgh, UK
3 shared publications - Amanda Parsons
Amanda Parsons, University of Birmingham, Primary Care Clinical Sciences, Edgbaston, Birmingham B15 2TT, UK
3 shared publications - Charlotte Albury
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 150, 109744
Challenges in advising people with severe mental illness to quit smoking: A conversation analysis of patient resistance
- 16 June 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 150, 109744
Open AccessChallenges in advising people with severe mental illness to quit smoking: A conversation analysis of patient resistance
- Open Access
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Challenges in Advising People with Serious Mental Illness to Quit Smoking: A Conversation Analysis of Patient Resistance
Objectives:People experiencing serious mental illness (SMI) smoke at a 2.5 times higher rate and have a lifespan shortened by 15-20 years compared to the general population, causing substantial health inequalities. This study aims to examine how quitting advice, provided by a primary care clinician (general practitioners and nurses) during scheduled annual health reviews, was resisted by people with SMI.Methods:Using conversation analysis (CA), we investigated 56 audio-recordings from a randomised controlled trial. We explored discussions about smoking turn-by-turn to identify patterns of resistance, and how primary care clinicians responded to patient resistance.Results:Analysis revealed two distinct patterns of resistance to smoking cessation advice: implicit rejection and explicit rejection. In implicit rejection sequences, patients foreground mental health concerns, thereby indicating that quitting cannot be acted upon at the moment. In explicit rejection sequences, patients rejected the advice with an explicit ‘no’ and expressed indifference to the health risks of smoking, presenting smoking as non-negotiable and making further discussion redundant. In both scenarios, clinicians responded with acknowledgements, neither explicitly agreeing with the patient nor pushing back on their resistance.Conclusions:Addressing smoking-related health inequalities among people with SMI is challenging because quitting is often deprioritised in the context of competing mental health and social concerns. These difficulties are compounded by clinicians’ challenges in raising and sustaining smoking cessation discussions. Recognising how resistance to quitting advice is interactionally produced can support more flexible and tailored cessation approaches that better align with patients’ priorities.Practice implications:This study highlights the unique resistance sequence presented in consultations advising people with SMI to quit smoking. It provides implications for clinical professionals to adopt more responsive and tailored responses to the resistance.
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessChallenges in Advising People with Serious Mental Illness to Quit Smoking: A Conversation Analysis of Patient Resistance
Objectives:People experiencing serious mental illness (SMI) smoke at a 2.5 times higher rate and have a lifespan shortened by 15-20 years compared to the general population, causing substantial health inequalities. This study aims to examine how quitting advice, provided by a primary care clinician (general practitioners and nurses) during scheduled annual health reviews, was resisted by people with SMI.Methods:Using conversation analysis (CA), we investigated 56 audio-recordings from a randomised controlled trial. We explored discussions about smoking turn-by-turn to identify patterns of resistance, and how primary care clinicians responded to patient resistance.Results:Analysis revealed two distinct patterns of resistance to smoking cessation advice: implicit rejection and explicit rejection. In implicit rejection sequences, patients foreground mental health concerns, thereby indicating that quitting cannot be acted upon at the moment. In explicit rejection sequences, patients rejected the advice with an explicit ‘no’ and expressed indifference to the health risks of smoking, presenting smoking as non-negotiable and making further discussion redundant. In both scenarios, clinicians responded with acknowledgements, neither explicitly agreeing with the patient nor pushing back on their resistance.Conclusions:Addressing smoking-related health inequalities among people with SMI is challenging because quitting is often deprioritised in the context of competing mental health and social concerns. These difficulties are compounded by clinicians’ challenges in raising and sustaining smoking cessation discussions. Recognising how resistance to quitting advice is interactionally produced can support more flexible and tailored cessation approaches that better align with patients’ priorities.Practice implications:This study highlights the unique resistance sequence presented in consultations advising people with SMI to quit smoking. It provides implications for clinical professionals to adopt more responsive and tailored responses to the resistance.
- Open Access
- 25 November 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (11) , CD016058
Interventions for quitting vaping
Rationale There is limited guidance on how to stop using nicotine‐containing vapes (otherwise known as e‐cigarettes) and ensure long‐term abstinence, whilst minimising the risk of tobacco smoking and other unintended consequences. Treatments could include pharmacological interventions, behavioural interventions, or both. Objectives To conduct a living systematic review assessing the benefits and harms of interventions to help people stop vaping compared to each other, placebo or no intervention. To assess how these interventions affect the use of combustible tobacco, and whether effects vary based on participant characteristics. Search methods We searched CENTRAL, MEDLINE, Embase, PsycINFO, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform from 1 January 2004 to 1 July 2025. We also searched the references of eligible studies and abstracts from the Society for Research on Nicotine and Tobacco conferences, and contacted study authors. Eligibility criteria We included randomised controlled trials (RCTs) recruiting people of any age using nicotine‐containing vapes, regardless of tobacco smoking status. Studies had to test an intervention designed to support people to quit vaping, and plan to measure at least one of our outcomes. Outcomes Critical outcomes: vaping cessation at six months or longer; change in combustible tobacco use at six months or longer; number of participants reporting serious adverse events (SAEs) at one week or longer. Risk of bias We used Cochrane's RoB 1 tool to assess risk of bias in the included studies. Synthesis methods We followed standard Cochrane methods. We grouped studies by comparisons and outcomes, and calculated individual study and pooled effects, as appropriate. We used random‐effects Mantel‐Haenszel methods to calculate risk ratios (RRs) with 95% confidence intervals (CIs) and random‐effects inverse variance methods to calculate mean differences (MDs) and 95% CIs. We used GRADE to assess the certainty of evidence for our critical outcomes. Included studies Fifteen studies (six new to this updated version) involving 5800 participants are included. Fourteen studies included some participants who had previously smoked tobacco; in seven studies, participants were not smoking at baseline. Twelve studies only included participants aged 18 or older (five exclusively included people between 18 and 29); two included some participants under 18 years; and one included 13‐ to 17‐year‐olds only. Fourteen studies were conducted in the USA and one in Italy. We judged five studies at low, six at high, and four at unclear risk of bias. Synthesis of results Pharmacological interventions Studies assessed our critical outcomes in relation to combination nicotine replacement therapy (NRT), cytisine, and varenicline compared to placebo or no/minimal support. For combination NRT versus no/minimal support, there was no clear evidence of benefit for vaping cessation rates at six months or longer, with the CI incorporating the possibility of reduced and increased cessation rates (very low‐certainty evidence due to imprecision and risk of bias; RR 0.96, 95% CI 0.73 to 1.25; I² = 0%; 2 studies, 214 participants). One study investigating cytisine versus placebo did not report vaping cessation at six months or longer. When compared to placebo, varenicline increased vaping cessation rates at six months, but evidence was of low certainty due to imprecision (RR 2.71, 95% CI 1.33 to 5.49; I2 = 48%; 2 studies, 315 participants). One study comparing combination NRT versus no/minimal support reported combustible tobacco cessation. There was no clear evidence of higher tobacco cessation in either arm, and CIs were imprecise. The evidence was of very low certainty due to imprecision and risk of bias (RR 0.99, 95% CI 0.71 to 1.37; 198 participants). Zero participants reported SAEs in the two studies investigating combination NRT versus no/minimal support (706 participants; very low‐certainty evidence due to risk of bias and imprecision) and in the one study investigating cytisine versus placebo (159 participants; low‐certainty evidence due to imprecision). Four studies evaluating varenicline versus placebo measured SAEs, with zero events reported in two studies. Thus, our effect estimate was based on two studies (RR 2.82, 95% CI 0.45 to 17.59; 304 participants; low‐certainty evidence due to imprecision). Behavioural interventions Studies assessed our critical outcomes in relation to reducing nicotine/vaping behaviour and text message‐based interventions compared to no/minimal support. There was no clear evidence that nicotine/vaping reduction increased vaping cessation at six months compared to minimal support (RR 3.38, 95% CI 0.43 to 26.30; 1 study, 17 participants; very low‐certainty evidence due to imprecision and risk of bias). There was low‐certainty evidence (due to indirectness) that text message‐based interventions may increase vaping cessation rates compared to no/minimal support in 13‐ to 24‐year‐olds specifically (RR 1.32, 95% CI 1.19 to 1.47; I2 = 0%; 2 studies, 4091 participants). There was very low‐certainty evidence (due to indirectness and imprecision) that text message‐based interventions for vaping cessation may result in little to no difference in smoking uptake (RR 1.04, 95% CI 0.81 to 1.33; 1 study, 1036 participants) or cessation (RR 1.03, 95% CI 0.90 to 1.19; 1 study, 793 participants) compared to no/minimal support. The one study investigating nicotine/vaping behaviour reduction versus minimal support did not report SAEs. Three studies investigating text message‐based interventions reported SAEs; however, zero events were reported (2082 participants; low‐certainty evidence due to imprecision). Authors' conclusions Low‐certainty evidence suggests that text message‐based interventions to help people stop nicotine vaping may help more youths and young adults to successfully stop compared to no/minimal support, with very uncertain evidence regarding their effect on smoking behaviours. Low‐certainty evidence suggests that varenicline may help people quit vaping. Data exploring the effectiveness of combination NRT, cytisine, and nicotine/vaping behaviour reduction are inconclusive due to risk of bias and imprecision. Most studies that measured SAEs reported that none had occurred; however, more data are needed to draw clear conclusions. Studies that have investigated these interventions for quitting smoking have not demonstrated serious concerns about SAEs. It is important that future studies measure combustible tobacco outcomes so the complete risk profile of relevant interventions can be considered. Further RCTs are underway. To ensure this review continues to provide up‐to‐date information to decision‐makers, we will maintain it as a living systematic review by running searches monthly and updating the review when relevant new evidence that will strengthen or change our conclusions emerges. Funding Cancer Research UK (PICCTR‐2024/100012); National Institute for Health and Care Research (NIHR206123). Registration Protocol (2024) DOI: 10.1002/14651858.CD016058 Original review (2025) DOI: 10.1002/14651858.CD016058.pub2
- 25 November 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (11) , CD016058
Open AccessInterventions for quitting vaping
Rationale There is limited guidance on how to stop using nicotine‐containing vapes (otherwise known as e‐cigarettes) and ensure long‐term abstinence, whilst minimising the risk of tobacco smoking and other unintended consequences. Treatments could include pharmacological interventions, behavioural interventions, or both. Objectives To conduct a living systematic review assessing the benefits and harms of interventions to help people stop vaping compared to each other, placebo or no intervention. To assess how these interventions affect the use of combustible tobacco, and whether effects vary based on participant characteristics. Search methods We searched CENTRAL, MEDLINE, Embase, PsycINFO, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform from 1 January 2004 to 1 July 2025. We also searched the references of eligible studies and abstracts from the Society for Research on Nicotine and Tobacco conferences, and contacted study authors. Eligibility criteria We included randomised controlled trials (RCTs) recruiting people of any age using nicotine‐containing vapes, regardless of tobacco smoking status. Studies had to test an intervention designed to support people to quit vaping, and plan to measure at least one of our outcomes. Outcomes Critical outcomes: vaping cessation at six months or longer; change in combustible tobacco use at six months or longer; number of participants reporting serious adverse events (SAEs) at one week or longer. Risk of bias We used Cochrane's RoB 1 tool to assess risk of bias in the included studies. Synthesis methods We followed standard Cochrane methods. We grouped studies by comparisons and outcomes, and calculated individual study and pooled effects, as appropriate. We used random‐effects Mantel‐Haenszel methods to calculate risk ratios (RRs) with 95% confidence intervals (CIs) and random‐effects inverse variance methods to calculate mean differences (MDs) and 95% CIs. We used GRADE to assess the certainty of evidence for our critical outcomes. Included studies Fifteen studies (six new to this updated version) involving 5800 participants are included. Fourteen studies included some participants who had previously smoked tobacco; in seven studies, participants were not smoking at baseline. Twelve studies only included participants aged 18 or older (five exclusively included people between 18 and 29); two included some participants under 18 years; and one included 13‐ to 17‐year‐olds only. Fourteen studies were conducted in the USA and one in Italy. We judged five studies at low, six at high, and four at unclear risk of bias. Synthesis of results Pharmacological interventions Studies assessed our critical outcomes in relation to combination nicotine replacement therapy (NRT), cytisine, and varenicline compared to placebo or no/minimal support. For combination NRT versus no/minimal support, there was no clear evidence of benefit for vaping cessation rates at six months or longer, with the CI incorporating the possibility of reduced and increased cessation rates (very low‐certainty evidence due to imprecision and risk of bias; RR 0.96, 95% CI 0.73 to 1.25; I² = 0%; 2 studies, 214 participants). One study investigating cytisine versus placebo did not report vaping cessation at six months or longer. When compared to placebo, varenicline increased vaping cessation rates at six months, but evidence was of low certainty due to imprecision (RR 2.71, 95% CI 1.33 to 5.49; I2 = 48%; 2 studies, 315 participants). One study comparing combination NRT versus no/minimal support reported combustible tobacco cessation. There was no clear evidence of higher tobacco cessation in either arm, and CIs were imprecise. The evidence was of very low certainty due to imprecision and risk of bias (RR 0.99, 95% CI 0.71 to 1.37; 198 participants). Zero participants reported SAEs in the two studies investigating combination NRT versus no/minimal support (706 participants; very low‐certainty evidence due to risk of bias and imprecision) and in the one study investigating cytisine versus placebo (159 participants; low‐certainty evidence due to imprecision). Four studies evaluating varenicline versus placebo measured SAEs, with zero events reported in two studies. Thus, our effect estimate was based on two studies (RR 2.82, 95% CI 0.45 to 17.59; 304 participants; low‐certainty evidence due to imprecision). Behavioural interventions Studies assessed our critical outcomes in relation to reducing nicotine/vaping behaviour and text message‐based interventions compared to no/minimal support. There was no clear evidence that nicotine/vaping reduction increased vaping cessation at six months compared to minimal support (RR 3.38, 95% CI 0.43 to 26.30; 1 study, 17 participants; very low‐certainty evidence due to imprecision and risk of bias). There was low‐certainty evidence (due to indirectness) that text message‐based interventions may increase vaping cessation rates compared to no/minimal support in 13‐ to 24‐year‐olds specifically (RR 1.32, 95% CI 1.19 to 1.47; I2 = 0%; 2 studies, 4091 participants). There was very low‐certainty evidence (due to indirectness and imprecision) that text message‐based interventions for vaping cessation may result in little to no difference in smoking uptake (RR 1.04, 95% CI 0.81 to 1.33; 1 study, 1036 participants) or cessation (RR 1.03, 95% CI 0.90 to 1.19; 1 study, 793 participants) compared to no/minimal support. The one study investigating nicotine/vaping behaviour reduction versus minimal support did not report SAEs. Three studies investigating text message‐based interventions reported SAEs; however, zero events were reported (2082 participants; low‐certainty evidence due to imprecision). Authors' conclusions Low‐certainty evidence suggests that text message‐based interventions to help people stop nicotine vaping may help more youths and young adults to successfully stop compared to no/minimal support, with very uncertain evidence regarding their effect on smoking behaviours. Low‐certainty evidence suggests that varenicline may help people quit vaping. Data exploring the effectiveness of combination NRT, cytisine, and nicotine/vaping behaviour reduction are inconclusive due to risk of bias and imprecision. Most studies that measured SAEs reported that none had occurred; however, more data are needed to draw clear conclusions. Studies that have investigated these interventions for quitting smoking have not demonstrated serious concerns about SAEs. It is important that future studies measure combustible tobacco outcomes so the complete risk profile of relevant interventions can be considered. Further RCTs are underway. To ensure this review continues to provide up‐to‐date information to decision‐makers, we will maintain it as a living systematic review by running searches monthly and updating the review when relevant new evidence that will strengthen or change our conclusions emerges. Funding Cancer Research UK (PICCTR‐2024/100012); National Institute for Health and Care Research (NIHR206123). Registration Protocol (2024) DOI: 10.1002/14651858.CD016058 Original review (2025) DOI: 10.1002/14651858.CD016058.pub2
- Open Access
- 29 April 2025
- Published by Wiley in Clinical Obesity
- Vol. 15 (5) , e70020
The implementation of a Nationally Enhanced Service incentive for weight management: A longitudinal qualitative study of the perceptions and experiences of UK primary care staff on weight management using normalisation process theory
Summary: In 2021 a Nationally Enhanced Service (NES) incentive for weight management in primary care was rolled out in England. This paid general practices £11.50 for every eligible referral they made to a weight management programme. We explored primary care staff's perceptions, experiences and attitudes toward the NES by conducting 37 semi‐structured interviews with General Practitioners (GPs), administrative staff and nurses preceding the introduction of the NES (May to September 2021) and 1 year later following its introduction (September to December 2022). Data were analysed using normalisation process theory. The NES for weight management solidified the position of staff already supportive of referring patients to weight management programmes. For staff less supportive of weight management services, the dissonance between the perceived lack of benefit of services and making referrals to services was reduced with referrals becoming more habitual. Facilitators to implementation included the presence of a coherent national policy; having a ‘champion’ explain key aspects; and a financial incentive if framed as benefiting the practice at large. Barriers included a perception that primary care has been shouldered with a complex and difficult health crisis; a worry over workload burdens; and inefficient and unclear referral systems. The implementation of the NES was broadly welcomed and accepted by primary care staff. Interviewees expressed concerns around the acceptance of weight management policies in primary care, the provision of training to raise the topic of weight and whether the responsibility of weight management fell with primary care, public health or with the patient.
- 29 April 2025
- Published by Wiley in Clinical Obesity
- Vol. 15 (5) , e70020
Open AccessThe implementation of a Nationally Enhanced Service incentive for weight management: A longitudinal qualitative study of the perceptions and experiences of UK primary care staff on weight management using normalisation process theory
Summary: In 2021 a Nationally Enhanced Service (NES) incentive for weight management in primary care was rolled out in England. This paid general practices £11.50 for every eligible referral they made to a weight management programme. We explored primary care staff's perceptions, experiences and attitudes toward the NES by conducting 37 semi‐structured interviews with General Practitioners (GPs), administrative staff and nurses preceding the introduction of the NES (May to September 2021) and 1 year later following its introduction (September to December 2022). Data were analysed using normalisation process theory. The NES for weight management solidified the position of staff already supportive of referring patients to weight management programmes. For staff less supportive of weight management services, the dissonance between the perceived lack of benefit of services and making referrals to services was reduced with referrals becoming more habitual. Facilitators to implementation included the presence of a coherent national policy; having a ‘champion’ explain key aspects; and a financial incentive if framed as benefiting the practice at large. Barriers included a perception that primary care has been shouldered with a complex and difficult health crisis; a worry over workload burdens; and inefficient and unclear referral systems. The implementation of the NES was broadly welcomed and accepted by primary care staff. Interviewees expressed concerns around the acceptance of weight management policies in primary care, the provision of training to raise the topic of weight and whether the responsibility of weight management fell with primary care, public health or with the patient.
- Top Cited PapersOpen Access
- 8 January 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (1) , CD016058
Interventions for quitting vaping
Rationale There is limited guidance on the best ways to stop using nicotine‐containing vapes (otherwise known as e‐cigarettes) and ensure long‐term abstinence, whilst minimising the risk of tobacco smoking and other unintended consequences. Treatments could include pharmacological interventions, behavioural interventions, or both. Objectives To conduct a living systematic review assessing the benefits and harms of interventions to help people stop vaping compared to each other or to placebo or no intervention. To also assess how these interventions affect the use of combustible tobacco, and whether the effects vary based on participant characteristics. Search methods We searched the following databases from 1 January 2004 to 24 April 2024: CENTRAL; MEDLINE; Embase; PsycINFO; ClinicalTrials.gov (through CENTRAL); World Health Organization International Clinical Trials Registry Platform (through CENTRAL). We also searched the references of eligible studies and abstracts from the Society for Research on Nicotine and Tobacco 2024 conference, and contacted study authors. Eligibility criteria Randomised controlled trials (RCTs) recruiting people of any age using nicotine‐containing vapes, regardless of tobacco smoking status. Studies had to test an intervention designed to support people to quit vaping, and plan to measure at least one of our outcomes. Outcomes Critical outcomes: vaping cessation; change in combustible tobacco use at six months or longer; number of participants reporting serious adverse events (SAEs) at one week or longer. Risk of bias We used the Cochrane RoB 1 tool to assess bias in the included studies. Synthesis methods We followed standard Cochrane methods for screening and data extraction. We grouped studies by comparisons and outcomes reported, and calculated individual study and pooled effects, as appropriate. We used random‐effects Mantel‐Haenszel methods to calculate risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes. We used random‐effects inverse variance methods to calculate mean differences and 95% CI for continuous outcomes. We assessed the certainty of the evidence using the GRADE approach. Included studies Nine RCTs, representing 5209 participants motivated to stop using nicotine‐containing vapes at baseline, are included. In six studies, participants were abstinent from smoking tobacco cigarettes at baseline, although most studies included some participants who had previously smoked. Eight studies included participants aged 18 or older, three included only young adults (18 to 24 years), and one included 13‐ to 17‐year‐olds only. We judged three studies at low risk, three at high risk, and three at unclear risk of bias. Synthesis of results Pharmacological interventions for quitting nicotine vaping Studies assessed combination nicotine replacement therapy (NRT), cytisine, and varenicline as pharmacological interventions for quitting vaping in comparison to placebo or no/minimal support (control). The point estimate for combination NRT indicated possible benefit, but the CI incorporated the possibility of no benefit and a potential benefit of control (very low‐certainty evidence due to imprecision and risk of bias; RR 2.57, 95% CI 0.29 to 22.93; 1 study, 16 participants). The one study investigating cytisine did not report vaping cessation rates at six months or longer. Varenicline increased vaping cessation rates at six months, but the evidence was low certainty due to imprecision (RR 2.00, 95% CI 1.09 to 3.68; 1 study, 140 participants). Zero participants reported SAEs in the studies of combination NRT versus no/minimal support (1 study, 508 participants; low‐certainty evidence due to imprecision) and cytisine versus placebo (1 study, 159 participants; low‐certainty evidence due to imprecision). Three studies investigating varenicline measured the number of participants reporting SAEs. However, only one study reported an SAE (in the intervention arm); therefore, the effect estimate was calculated based on that single study (RR 2.60, 95% CI 0.11 to 62.16; 95 participants; low‐certainty evidence due to imprecision). Behavioural interventions for quitting nicotine vaping Studies assessed reducing nicotine concentration and vaping behaviour (1 study) and text message‐based interventions (3 studies) as behavioural interventions for stopping vaping in comparison to no/minimal support (control). In one study, the point estimate suggested nicotine/vaping reduction increased vaping cessation compared to minimal support at six‐month follow‐up, but the CI incorporated the possibility of no intervention effect and higher cessation rates in the control arm (RR 3.38, 95% CI 0.43 to 26.30; 17 participants; very low‐certainty due to imprecision and risk of bias). There was low‐certainty evidence (downgraded two levels due to indirectness) that text message‐based interventions may have increased vaping cessation rates compared to control in 13‐ to 24‐year‐olds (RR 1.32, 95% CI 1.19 to 1.47; I2 = 0%; 2 studies, 4091 participants). The one study investigating nicotine/vaping behaviour reduction did not report on SAEs. One of the studies investigating text message‐based interventions did report on SAEs; however, zero events were reported in both study arms (508 participants; low‐certainty evidence due to imprecision). No studies reported change in combustible tobacco smoking at six‐month follow‐up or longer. Authors' conclusions There is low‐certainty evidence that text message‐based interventions designed to help people stop nicotine vaping may help more youth and young adults to successfully stop than no/minimal support, and low‐certainty evidence that varenicline may also help people quit vaping. Data exploring the effectiveness of combination NRT, cytisine, and nicotine/vaping behaviour reduction are inconclusive due to risk of bias and imprecision. Most studies that measured SAEs reported none; however, more data are needed to draw clear conclusions. Of note, data from studies investigating these interventions for quitting smoking have not demonstrated serious concerns about SAEs. No studies assessed the change in combustible tobacco smoking, including relapse to or uptake of tobacco smoking, at six‐month follow‐up or longer. It is important that future studies measure this so the complete risk profile of relevant interventions can be considered. We identified 20 ongoing RCTs. Their incorporation into the evidence base and the continued identification of new studies is imperative to inform clinical and policy guidance on the best ways to stop vaping. Therefore, we will continue to update this review as a living systematic review by running searches monthly and updating the review when relevant new evidence that will strengthen or change our conclusions emerges. Funding Cancer Research UK (PRCPJT‐Nov22/100012). National Institute of Health Research (NIHR206123) Registration Protocol available via DOI: 10.1002/14651858.CD016058.
- 8 January 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (1) , CD016058
Top Cited PapersOpen AccessInterventions for quitting vaping
Rationale There is limited guidance on the best ways to stop using nicotine‐containing vapes (otherwise known as e‐cigarettes) and ensure long‐term abstinence, whilst minimising the risk of tobacco smoking and other unintended consequences. Treatments could include pharmacological interventions, behavioural interventions, or both. Objectives To conduct a living systematic review assessing the benefits and harms of interventions to help people stop vaping compared to each other or to placebo or no intervention. To also assess how these interventions affect the use of combustible tobacco, and whether the effects vary based on participant characteristics. Search methods We searched the following databases from 1 January 2004 to 24 April 2024: CENTRAL; MEDLINE; Embase; PsycINFO; ClinicalTrials.gov (through CENTRAL); World Health Organization International Clinical Trials Registry Platform (through CENTRAL). We also searched the references of eligible studies and abstracts from the Society for Research on Nicotine and Tobacco 2024 conference, and contacted study authors. Eligibility criteria Randomised controlled trials (RCTs) recruiting people of any age using nicotine‐containing vapes, regardless of tobacco smoking status. Studies had to test an intervention designed to support people to quit vaping, and plan to measure at least one of our outcomes. Outcomes Critical outcomes: vaping cessation; change in combustible tobacco use at six months or longer; number of participants reporting serious adverse events (SAEs) at one week or longer. Risk of bias We used the Cochrane RoB 1 tool to assess bias in the included studies. Synthesis methods We followed standard Cochrane methods for screening and data extraction. We grouped studies by comparisons and outcomes reported, and calculated individual study and pooled effects, as appropriate. We used random‐effects Mantel‐Haenszel methods to calculate risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes. We used random‐effects inverse variance methods to calculate mean differences and 95% CI for continuous outcomes. We assessed the certainty of the evidence using the GRADE approach. Included studies Nine RCTs, representing 5209 participants motivated to stop using nicotine‐containing vapes at baseline, are included. In six studies, participants were abstinent from smoking tobacco cigarettes at baseline, although most studies included some participants who had previously smoked. Eight studies included participants aged 18 or older, three included only young adults (18 to 24 years), and one included 13‐ to 17‐year‐olds only. We judged three studies at low risk, three at high risk, and three at unclear risk of bias. Synthesis of results Pharmacological interventions for quitting nicotine vaping Studies assessed combination nicotine replacement therapy (NRT), cytisine, and varenicline as pharmacological interventions for quitting vaping in comparison to placebo or no/minimal support (control). The point estimate for combination NRT indicated possible benefit, but the CI incorporated the possibility of no benefit and a potential benefit of control (very low‐certainty evidence due to imprecision and risk of bias; RR 2.57, 95% CI 0.29 to 22.93; 1 study, 16 participants). The one study investigating cytisine did not report vaping cessation rates at six months or longer. Varenicline increased vaping cessation rates at six months, but the evidence was low certainty due to imprecision (RR 2.00, 95% CI 1.09 to 3.68; 1 study, 140 participants). Zero participants reported SAEs in the studies of combination NRT versus no/minimal support (1 study, 508 participants; low‐certainty evidence due to imprecision) and cytisine versus placebo (1 study, 159 participants; low‐certainty evidence due to imprecision). Three studies investigating varenicline measured the number of participants reporting SAEs. However, only one study reported an SAE (in the intervention arm); therefore, the effect estimate was calculated based on that single study (RR 2.60, 95% CI 0.11 to 62.16; 95 participants; low‐certainty evidence due to imprecision). Behavioural interventions for quitting nicotine vaping Studies assessed reducing nicotine concentration and vaping behaviour (1 study) and text message‐based interventions (3 studies) as behavioural interventions for stopping vaping in comparison to no/minimal support (control). In one study, the point estimate suggested nicotine/vaping reduction increased vaping cessation compared to minimal support at six‐month follow‐up, but the CI incorporated the possibility of no intervention effect and higher cessation rates in the control arm (RR 3.38, 95% CI 0.43 to 26.30; 17 participants; very low‐certainty due to imprecision and risk of bias). There was low‐certainty evidence (downgraded two levels due to indirectness) that text message‐based interventions may have increased vaping cessation rates compared to control in 13‐ to 24‐year‐olds (RR 1.32, 95% CI 1.19 to 1.47; I2 = 0%; 2 studies, 4091 participants). The one study investigating nicotine/vaping behaviour reduction did not report on SAEs. One of the studies investigating text message‐based interventions did report on SAEs; however, zero events were reported in both study arms (508 participants; low‐certainty evidence due to imprecision). No studies reported change in combustible tobacco smoking at six‐month follow‐up or longer. Authors' conclusions There is low‐certainty evidence that text message‐based interventions designed to help people stop nicotine vaping may help more youth and young adults to successfully stop than no/minimal support, and low‐certainty evidence that varenicline may also help people quit vaping. Data exploring the effectiveness of combination NRT, cytisine, and nicotine/vaping behaviour reduction are inconclusive due to risk of bias and imprecision. Most studies that measured SAEs reported none; however, more data are needed to draw clear conclusions. Of note, data from studies investigating these interventions for quitting smoking have not demonstrated serious concerns about SAEs. No studies assessed the change in combustible tobacco smoking, including relapse to or uptake of tobacco smoking, at six‐month follow‐up or longer. It is important that future studies measure this so the complete risk profile of relevant interventions can be considered. We identified 20 ongoing RCTs. Their incorporation into the evidence base and the continued identification of new studies is imperative to inform clinical and policy guidance on the best ways to stop vaping. Therefore, we will continue to update this review as a living systematic review by running searches monthly and updating the review when relevant new evidence that will strengthen or change our conclusions emerges. Funding Cancer Research UK (PRCPJT‐Nov22/100012). National Institute of Health Research (NIHR206123) Registration Protocol available via DOI: 10.1002/14651858.CD016058.
- Open Access
- 31 January 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (4)
Clinician–patient communication about emergency aerial medical evacuation in case of infectious disease
Aerial medical evacuation (AME) refers to the removal of patients from one site to a medical facility elsewhere using medically equipped air ambulances. 1 In cases of certain infectious diseases it may be necessary to isolate patients in a patient isolation unit (PIU) or ‘pod’ during AME to reduce the risk of transmission of infection to others. Used to transfer patients within and between countries during outbreaks of infectious disease, 2 during the COVID-19 pandemic AME became an area of ongoing need. 3 With projections indicating current increases in pandemics will likely continue, 4 the need for AME will do the same. However, AME in case of infectious disease is an under researched area. There is limited information about the processes and procedures of AME in case of infectious disease, 5 and no research or guidance on how to communicate these to patients. A 2019 systematic review aimed to evaluate the processes and procedures used, including pre-flight, in-flight and post-flight. 6 The review highlighted the importance of effective communication, but identified a dearth of studies in this area, with just one study detailing communication with patients during the flight, and none examining pre-flight communication.
- 31 January 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (4)
Open AccessClinician–patient communication about emergency aerial medical evacuation in case of infectious disease
Aerial medical evacuation (AME) refers to the removal of patients from one site to a medical facility elsewhere using medically equipped air ambulances. 1 In cases of certain infectious diseases it may be necessary to isolate patients in a patient isolation unit (PIU) or ‘pod’ during AME to reduce the risk of transmission of infection to others. Used to transfer patients within and between countries during outbreaks of infectious disease, 2 during the COVID-19 pandemic AME became an area of ongoing need. 3 With projections indicating current increases in pandemics will likely continue, 4 the need for AME will do the same. However, AME in case of infectious disease is an under researched area. There is limited information about the processes and procedures of AME in case of infectious disease, 5 and no research or guidance on how to communicate these to patients. A 2019 systematic review aimed to evaluate the processes and procedures used, including pre-flight, in-flight and post-flight. 6 The review highlighted the importance of effective communication, but identified a dearth of studies in this area, with just one study detailing communication with patients during the flight, and none examining pre-flight communication.
- Open Access
- 4 June 2020
- Published by Wiley in The Journal of Physiology
- Vol. 598 (15) , 3049-3051
CrossTalk proposal: The benefits of e‐cigarettes outweigh the harms
- 4 June 2020
- Published by Wiley in The Journal of Physiology
- Vol. 598 (15) , 3049-3051
Open AccessCrossTalk proposal: The benefits of e‐cigarettes outweigh the harms
- Open Access
- 4 June 2020
- Published by Wiley in The Journal of Physiology
- Vol. 598 (15) , 3057
Rebuttal from Rachna Begh and Paul Aveyard
- 4 June 2020
- Published by Wiley in The Journal of Physiology
- Vol. 598 (15) , 3057
Open AccessRebuttal from Rachna Begh and Paul Aveyard
- Open Access
- 28 November 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-16
Examining the effectiveness of general practitioner and nurse promotion of electronic cigarettes versus standard care for smoking reduction and abstinence in hardcore smokers with smoking-related chronic disease: protocol for a randomised controlled trial
Background: Despite the clear harm associated with smoking tobacco, many people with smoking-related chronic diseases or serious mental illnesses (SMI) are unwilling or unable to stop smoking. In many cases, these smokers have tried and exhausted all methods to stop smoking and yet clinicians are repeatedly mandated to offer them during routine consultations. Providing nicotine through electronic cigarettes (e-cigarettes) may reduce the adverse health consequences associated with tobacco smoking, but these are not currently offered. The aim of this study is to examine the feasibility, acceptability and effectiveness of general practitioners (GPs) and nurses delivering a brief advice intervention on e-cigarettes and offering an e-cigarette starter pack and patient support resources compared with standard care in smokers with smoking-related chronic diseases or SMI who are unwilling to stop smoking. Methods/design: This is an individually randomised, blinded, two-arm trial. Smokers with a smoking-related chronic condition or SMI with no intention of stopping smoking will be recruited through primary care registers. Eligible participants will be randomised to one of two groups if they decline standard care for stopping smoking: a control group who will receive no additional support beyond standard care; or an intervention group who will receive GP or nurse-led brief advice about e-cigarettes, an e-cigarette starter pack with accompanying practical support booklet, and telephone support from experienced vapers and online video tutorials. The primary outcome measures will be smoking reduction, measured through changes in cigarettes per day and 7-day point-prevalence abstinence at 2 months. Secondary outcomes include smoking reduction, 7-day point-prevalence abstinence and prolonged abstinence at 8 months. Other outcomes include patient recruitment and follow-up, patient uptake and use of e-cigarettes, nicotine intake, contamination of randomisation and practitioner adherence to the delivery of the intervention. Qualitative interviews will be conducted in a subsample of practitioners, patients and the vape team to garner their reactions to the programme. Discussion: This is the first randomised controlled trial to investigate whether e-cigarette provision alongside a brief intervention delivered by practitioners leads to reduced smoking and abstinence among smokers with smoking-related chronic diseases or SMI. Trial registration: ISRCTN registry, ISRCTN59404712. Registered 28/11/17.
- 28 November 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-16
Open AccessExamining the effectiveness of general practitioner and nurse promotion of electronic cigarettes versus standard care for smoking reduction and abstinence in hardcore smokers with smoking-related chronic disease: protocol for a randomised controlled trial
Background: Despite the clear harm associated with smoking tobacco, many people with smoking-related chronic diseases or serious mental illnesses (SMI) are unwilling or unable to stop smoking. In many cases, these smokers have tried and exhausted all methods to stop smoking and yet clinicians are repeatedly mandated to offer them during routine consultations. Providing nicotine through electronic cigarettes (e-cigarettes) may reduce the adverse health consequences associated with tobacco smoking, but these are not currently offered. The aim of this study is to examine the feasibility, acceptability and effectiveness of general practitioners (GPs) and nurses delivering a brief advice intervention on e-cigarettes and offering an e-cigarette starter pack and patient support resources compared with standard care in smokers with smoking-related chronic diseases or SMI who are unwilling to stop smoking. Methods/design: This is an individually randomised, blinded, two-arm trial. Smokers with a smoking-related chronic condition or SMI with no intention of stopping smoking will be recruited through primary care registers. Eligible participants will be randomised to one of two groups if they decline standard care for stopping smoking: a control group who will receive no additional support beyond standard care; or an intervention group who will receive GP or nurse-led brief advice about e-cigarettes, an e-cigarette starter pack with accompanying practical support booklet, and telephone support from experienced vapers and online video tutorials. The primary outcome measures will be smoking reduction, measured through changes in cigarettes per day and 7-day point-prevalence abstinence at 2 months. Secondary outcomes include smoking reduction, 7-day point-prevalence abstinence and prolonged abstinence at 8 months. Other outcomes include patient recruitment and follow-up, patient uptake and use of e-cigarettes, nicotine intake, contamination of randomisation and practitioner adherence to the delivery of the intervention. Qualitative interviews will be conducted in a subsample of practitioners, patients and the vape team to garner their reactions to the programme. Discussion: This is the first randomised controlled trial to investigate whether e-cigarette provision alongside a brief intervention delivered by practitioners leads to reduced smoking and abstinence among smokers with smoking-related chronic diseases or SMI. Trial registration: ISRCTN registry, ISRCTN59404712. Registered 28/11/17.
- Open Access
- 31 January 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 43 (10) , 2066-2075
Screening and brief intervention for obesity in primary care: cost-effectiveness analysis in the BWeL trial
Background The Brief Intervention for Weight Loss Trial enrolled 1882 consecutively attending primary care patients who were obese and participants were randomised to physicians opportunistically endorsing, offering, and facilitating a referral to a weight loss programme (support) or recommending weight loss (advice). After one year, the support group lost 1.4 kg more (95%CI 0.9 to 2.0): 2.4 kg versus 1.0 kg. We use a cohort simulation to predict effects on disease incidence, quality of life, and healthcare costs over 20 years. Methods Randomly sampling from the trial population, we created a virtual cohort of 20 million adults and assigned baseline morbidity. We applied the weight loss observed in the trial and assumed weight regain over four years. Using epidemiological data, we assigned the incidence of 12 weight-related diseases depending on baseline disease status, age, gender, body mass index. From a healthcare perspective, we calculated the quality adjusted life years (QALYs) accruing and calculated the incremental difference between trial arms in costs expended in delivering the intervention and healthcare costs accruing. We discounted future costs and benefits at 1.5% over 20 years. Results Compared with advice, the support intervention reduced the cumulative incidence of weight-related disease by 722/100,000 people, 0.33% of all weight-related disease. The incremental cost of support over advice was £2.01million/100,000. However, the support intervention reduced health service costs by £5.86 million/100,000 leading to a net saving of £3.85 million/100,000. The support intervention produced 992 QALYs/100,000 people relative to advice. Conclusions A brief intervention in which physicians opportunistically endorse, offer, and facilitate a referral to a behavioural weight management service to patients with a BMI of at least 30 kg/m2 reduces healthcare costs and improves health more than advising weight loss.
- 31 January 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 43 (10) , 2066-2075
Open AccessScreening and brief intervention for obesity in primary care: cost-effectiveness analysis in the BWeL trial
Background The Brief Intervention for Weight Loss Trial enrolled 1882 consecutively attending primary care patients who were obese and participants were randomised to physicians opportunistically endorsing, offering, and facilitating a referral to a weight loss programme (support) or recommending weight loss (advice). After one year, the support group lost 1.4 kg more (95%CI 0.9 to 2.0): 2.4 kg versus 1.0 kg. We use a cohort simulation to predict effects on disease incidence, quality of life, and healthcare costs over 20 years. Methods Randomly sampling from the trial population, we created a virtual cohort of 20 million adults and assigned baseline morbidity. We applied the weight loss observed in the trial and assumed weight regain over four years. Using epidemiological data, we assigned the incidence of 12 weight-related diseases depending on baseline disease status, age, gender, body mass index. From a healthcare perspective, we calculated the quality adjusted life years (QALYs) accruing and calculated the incremental difference between trial arms in costs expended in delivering the intervention and healthcare costs accruing. We discounted future costs and benefits at 1.5% over 20 years. Results Compared with advice, the support intervention reduced the cumulative incidence of weight-related disease by 722/100,000 people, 0.33% of all weight-related disease. The incremental cost of support over advice was £2.01million/100,000. However, the support intervention reduced health service costs by £5.86 million/100,000 leading to a net saving of £3.85 million/100,000. The support intervention produced 992 QALYs/100,000 people relative to advice. Conclusions A brief intervention in which physicians opportunistically endorse, offer, and facilitate a referral to a behavioural weight management service to patients with a BMI of at least 30 kg/m2 reduces healthcare costs and improves health more than advising weight loss.